15 assets in Rectal Neoplasm

Therapeutic assets addressing Rectal Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fluorouracilum Rectal Neoplasm	Pei-Rong Ding	P3	BB (68)
Oxaliplatin Rectal Neoplasm	Chongqing University Cancer Hospital	P3	BB (68)
Capecitabine Rectal Neoplasm	Chongqing University Cancer Hospital	P3	BB (66)
Atezolizumab Rectal Neoplasm	Hoffmann-La Roche	P2	BB (65)
Tislelizumab Rectal Neoplasm	Fudan University	P3	BB (64)
Dostarlimab Rectal Neoplasm	GlaxoSmithKline	P2	B (60)
Irinotecan Rectal Neoplasm	Pei-Rong Ding	P2	B (57)
Chlorophyllin Copper Complex Sodium Rectal Neoplasm	Tata Memorial Centre	P2	CCC (53)
Chlorophyllin, Sodium Copper Complex Rectal Neoplasm	Tata Memorial Centre	P2	CCC (53)
Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101) Rectal Neoplasm	Chongqing University Cancer Hospital	P2	CCC (53)
Serplulimab Rectal Neoplasm	Chongqing University Cancer Hospital	P2	CCC (53)
Sgm-101 Rectal Neoplasm	Leiden University Medical Center	P2	CCC (53)
Tiragolumab Rectal Neoplasm	Hoffmann-La Roche	P2	CCC (53)
Niraparib Rectal Neoplasm	University of Iowa	P1	CC (43)
Dexmedetomidine Rectal Neoplasm	The Second Affiliated Hospital of Chongqing Medical University	N/A	NR ()